文献速递产科

剖宫产预防性抗生素加用阿奇霉素的临床效果

Clinical effectiveness of adding azithromycin to antimicrobial prophylaxis for cesarean delivery.
PubMed 文献 · Am J Obstet Gynecol · 2021-05-27

本研究为前后队列研究,评估剖宫产术前预防性抗生素加用阿奇霉素的临床效果。实施前组(n=1171)和實施後組(n=1168)术后感染复合结局发生率分别为4.7%和5.3%(P=.49),校正相对风险为1.06(95%CI 0.74-1.52),无显著差异。结论提示临床实践中加用阿奇霉素的效果可能小于大型临床试验所示,且对未临产妇女可能无效。

要点

  • 剖宫产术前预防性抗生素加用阿奇霉素后,术后感染复合结局无显著下降。
  • 临产和/或胎膜破裂≥4小时亚组感染率方向偏低但无统计学意义。
  • 未临产妇女加用阿奇霉素后感染风险无显著增加,但方向偏高。

核心结论

  • 临床实践中剖宫产预防性抗生素加用阿奇霉素的效果可能小于大型临床试验所示。
  • 将方案外推至未临产妇女可能无效。

研究设计与样本

  • 前后队列研究,实施前组为2016年3月1日至2017年2月28日剖宫产妇女(n=1171)。
  • 实施后组为2017年9月1日至2018年8月31日剖宫产妇女(n=1168),期间留6个月实践推广期。

主要发现

  • 实施前组和實施後組术后感染复合结局发生率分别为4.7%和5.3%(P=.49)。
  • 未校正相对风险为1.13(95%CI 0.78-1.62),校正相对风险为1.06(95%CI 0.74-1.52),均无统计学意义。
  • 临产和/或胎膜破裂≥4小时亚组:相对风险0.88(95%CI 0.56-1.39),校正相对风险0.82(95%CI 0.52-1.30)。
  • 临床绒毛膜羊膜炎亚组:相对风险0.37(95%CI 0.08-1.67),数据过少未行校正分析。
  • 未临产亚组:未校正相对风险1.53(95%CI 0.86-2.72),校正相对风险1.48(95%CI 0.83-2.65),均无统计学意义。

临床怎么用

  • 临床实践中加用阿奇霉素的获益可能小于既往大型试验,需结合本地数据评估。
  • 未临产妇女常规加用阿奇霉素可能无效,应避免盲目外推。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: A recent large clinical trial demonstrated an approximately 50% decrease in the rate of postoperative infection in women who were laboring and/or had rupture of membranes for >4 hours and who received azithromycin in addition to standard preoperative antibiotic prophylaxis at the time of cesarean delivery. Given these results, our institution made a policy change in May 2017 to add azithromycin to standard preoperative prophylaxis for all cesarean deliveries. OBJECTIVE: This study aimed to evaluate the clinical effectiveness of adding azithromycin to preoperative antibiotic prophylaxis for cesarean delivery. STUDY DESIGN: We conducted a before-and-after cohort study of women delivered via cesarean delivery at our institution. The preimplementation group included women who delivered from March 1, 2016, to February 28, 2017, (before an institutional practice change of adding azithromycin to standard preoperative prophylaxis), and the postimplementation group included women who delivered from September 1, 2017, to August 31, 2018 (allowing a 6-month period for uptake of the practice change). The primary outcome was a composite of postoperative infections (endometritis, wound infection, other maternal infections). Unadjusted and adjusted risk ratios and 95% confidence intervals were estimated using a modified Poisson regression model. RESULTS: In the preimplementation (n=1171) and postimplementation (n=1168) groups, the incidence rates of the composite outcomes were 4.7% and 5.3%, respectively (P=.49). Both unadjusted (relative risk, 1.13; 95% confidence interval, 0.78-1.62) and adjusted (adjusted relative risk, 1.06; 95% confidence interval, 0.74-1.52) comparisons were not significantly different. In addition, results were statistically nonsignificant, but in the direction of lower rates of infection, in the after cohort for women in labor and/or with rupture of membranes for ≥4 hours (relative risk, 0.88 [95% confidence interval, 0.56-1.39]; adjusted relative risk, 0.82 [95% confidence interval, 0.52-1.30]) and for women with clinical chorioamnionitis (relative risk, 0.37 [95% confidence interval, 0.08-1.67]; data too sparse for adjusted analysis). In the subgroup of women who were not in labor, the after cohort had a statistically nonsignificant increased risk of the composite outcome in both unadjusted (relative risk, 1.53; 95% confidence interval, 0.86-2.72) and adjusted (adjusted relative risk, 1.48; 95% confidence interval, 0.83-2.65]) comparisons. CONCLUSION: In clinical practice, the addition of azithromycin to standard preoperative antibiotic prophylaxis for cesarean delivery may have an effect size smaller than seen in the large clinical trial prompting this practice change. Extrapolation of this regimen to women not in labor may be ineffective.

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Pierce SL, Bisson CM, Dubois ME, et al. Clinical effectiveness of adding azithromycin to antimicrobial prophylaxis for cesarean delivery. Am J Obstet Gynecol. 2021. PMID: 34052192. doi:10.1016/j.ajog.2021.05.023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。